Dr. Martens (DOCS) Share Price, News & Analysis

Company Overview

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over 60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the 1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and accessories. The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and is a constituent of the FTSE 250 index. Dr. Martens operates across three geographic regions: EMEA, Americas and APAC. Our product segments include Originals, Fusion, Kids and Casual and a complementary range of Accessories.

Key Stats

• Today's Range: 91.10 to 92.85
• 50-Day Range: 74.69 to 93.80
• 52-Week Range: 43.02 to 96.50
• Volume: 552,404 shs
• Average Volume: 2.14 million shs
• Market Capitalization: £883.58 million
• P/E Ratio: 18,300.00
• Dividend Yield: 0.02%
• Price Target: GBX 6,000
• Consensus Rating: Hold

Dr. Martens Stock Analysis - MarketRank™

Dr. Martens scored higher than 29% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Dr. Martens has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

Upside Potential

Dr. Martens has a consensus price target of GBX 6,000, representing about 6,457.4% upside from its current price of GBX 91.50.

Amount of Analyst Coverage

Dr. Martens has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Dr. Martens is 18,300.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 280.45.

Price to Earnings Ratio vs. Sector

The P/E ratio of Dr. Martens is 18,300.00, which means that it is trading at a more expensive P/E ratio than the Consumer Cyclical sector average P/E ratio of about 527.01.

Price to Earnings Growth Ratio

Dr. Martens has a PEG Ratio of 6.40. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Dr. Martens has a P/B Ratio of 2.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for DOCS.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

Dr. Martens pays a meaningful dividend of 2.82%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Dr. Martens does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Dr. Martens is 368.00%. Payout ratios above 75% are not desirable because they may not be sustainable.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for DOCS.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

Only 5 people have searched for DOCS on MarketBeat in the last 30 days. This is a decrease of -69% compared to the previous 30 days.

MarketBeat Follows

1 people have added Dr. Martens to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Dr. Martens insiders have bought 1.53% more of their company's stock than they have sold. Specifically, they have bought £124,377.69 in company stock and sold £122,506.50 in company stock.

Percentage Held by Insiders

Only 2.76% of the stock of Dr. Martens is held by insiders.

Percentage Held by Institutions

Only 32.11% of the stock of Dr. Martens is held by institutions.

DOCS Stock Analysis - Frequently Asked Questions

How have DOCS shares performed this year?

Dr. Martens' stock was trading at GBX 72.20 at the beginning of 2025. Since then, DOCS stock has increased by 26.7% and is now trading at GBX 91.50.

How were Dr. Martens' earnings last quarter?

Dr. Martens plc (LON:DOCS) issued its quarterly earnings results on Thursday, June, 5th. The company reported $2.40 earnings per share for the quarter. Dr. Martens had a trailing twelve-month return on equity of 18.91% and a net margin of 7.89%.
Read the conference call transcript.

How do I buy shares of Dr. Martens?

Shares of DOCS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Dr. Martens own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Dr. Martens investors own include boohoo group (BOO), Aston Martin Lagonda Global (AML), ASOS (ASC), Vodafone Group Public (VOD), JD Sports Fashion (JD), Legal & General Group (LGEN) and Lloyds Banking Group (LLOY).

Company Calendar

• Last Earnings: 6/05/2025
• Today: 9/25/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Consumer Cyclical
• Industry: Footwear & Accessories
• Sub-Industry: Computer Software
• Current Symbol: LON:DOCS
• CIK: N/A
• Web: www.drmartensplc.com
• Phone: 44 12 1415 7047
• Fax: N/A
• Employees: 890
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Dr. Martens: GBX 6,000
• High Price Target: GBX 6,000
• Low Price Target: GBX 6,000
• Potential Upside/Downside: +6,457.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): GBX 0.01
• Trailing P/E Ratio: 18,300.00
• Forward P/E Ratio: 35.45
• P/E Growth: 6.4
• Net Income: £68.97 million
• Net Margins: 7.89%
• Pretax Margin: N/A
• Return on Equity: 18.91%
• Return on Assets: 8.12%

Debt

• Debt-to-Equity Ratio: 127.27
• Current Ratio: 2.85
• Quick Ratio: 1.13

Sales & Book Value

• Annual Sales: £787.60 million
• Price / Sales: 1.12
• Cash Flow: GBX 6.41 per share
• Price / Cash Flow: 14.29
• Book Value: GBX 37.80 per share
• Price / Book: 2.42

Miscellaneous

• Outstanding Shares: 965,666,000
• Free Float: N/A
• Market Cap: £883.58 million
• Optionable: Not Optionable
• Beta: 0.11